FDA, CDC Lift Suspension Of Johnson & Johnson Vaccine
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The US Food and Drug Administration (FDA) will add a warning to the Johnson and Johnson one-dose COVID vaccine and lift its recommended pause on the shots. The agency acted quickly to get the vaccine back into distribution after a Centers for Disease Control and Prevention (CDC) advisory panel met on Friday and voted to continue to recommend its use in adults ages 18 and up.

The vote came after the CDC and the FDA conducted a safety review of 15 cases of thrombosis-thrombocytopenia Syndrome (TTS) that occurred in women ages 18 to 59 within a few weeks of getting their vaccines. Three of the women died. Seven have been treated in intensive care units.

"What we are seeing is the overall rate of events was 1.9 cases per million people. In women 18 to 29 years there was an approximate 7 cases per million. The risk is even lower in women over the age of 50, at .9 cases per million," said CDC Director Rochelle Walensky, MD. In the end, the potential benefits of the vaccine far outweighed its risks.

"In terms of benefits, we found that for every 1 million doses of this vaccine, the vaccine could prevent over 650 hospitalizations and 12 deaths among women ages 18-49,” Walensky said. The potential benefits to women over 50 were even greater: It could prevent 4700 hospitalizations and 650 deaths.

"In the end, this vaccine was shown to be safe and effective for the vast majority of people," Walensky said. She pointed out that over the past few days, as regulators have reviewed the rare events, newly identified patients had been treated appropriately, without the use of heparin, which is not advised with TTS.

Dr. T●●●●z H●●●●●●i and 2 other likes this2 shares